Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTSO Stock Forecast 2026-2027
$0.37
Current Price
$24.44M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CTSO Price Targets
+1,253.5%
To High Target of $5.00
+678.3%
To Median Target of $2.88
+103.0%
To Low Target of $0.75
CTSO Price Momentum
-2.6%
1 Week Change
-22.9%
1 Month Change
-62.6%
1 Year Change
-42.2%
Year-to-Date Change
-69.7%
From 52W High of $1.22
+5.5%
From 52W Low of $0.35
📊 TOP ANALYST CALLS
Did CTSO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CytoSorbents is one of their latest high-conviction picks.
Latest CTSO Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CTSO has a neutral consensus with a median price target of $2.88 (ranging from $0.75 to $5.00). The overall analyst rating is Buy (6.0/10). Currently trading at $0.37, the median forecast implies a 678.3% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTSO Analyst Ratings
0
Buy
1
Hold
0
Sell
CTSO Price Target Range
Low
$0.75
Average
$2.88
High
$5.00
Current: $0.37
Latest CTSO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTSO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jan 12, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 16, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 14, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 14, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Sep 16, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 20, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 8, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jul 21, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 25, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| May 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| May 15, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| May 2, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 3, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Apr 1, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 25, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 13, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 3, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 12, 2024 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A |
Cytosorbents Corporation (CTSO) Competitors
The following stocks are similar to CytoSorbents based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytosorbents Corporation (CTSO) Financial Data
Cytosorbents Corporation has a market capitalization of $24.44M with a P/E ratio of -3.0x. The company generates $37.20M in trailing twelve-month revenue with a -31.8% profit margin.
Revenue growth is +1.6% quarter-over-quarter, while maintaining an operating margin of -34.3% and return on equity of -141.6%.
Valuation Metrics
Market Cap
$24.44M
Enterprise Value
$48.33M
P/E Ratio
-3.0x
PEG Ratio
0.0x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
+1.6%
Gross Margin
+69.2%
Operating Margin
-34.3%
Net Margin
-31.8%
EPS Growth
+1.6%
Financial Health
Cash/Price Ratio
+20.8%
Current Ratio
1.1x
Debt/Equity
1,334.4x
ROE
-141.6%
ROA
-18.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cytosorbents Corporation (CTSO) Business Model
About Cytosorbents Corporation
What They Do
Develops advanced blood purification technologies.
Business Model
Cytosorbents Corporation generates revenue primarily through the sales of its flagship product, CytoSorb, a hemoadsorption cartridge that treats severe inflammatory conditions by removing harmful cytokines from the blood. The company operates in the healthcare sector, targeting intensive care units and hospital settings, and aims to enhance patient outcomes through innovative medical solutions.
Additional Information
Headquartered in Princeton, New Jersey, Cytosorbents is actively involved in clinical trials and partnerships to expand its global reach and improve the adoption of its technologies in critical care and immunotherapy applications.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
129
CEO
Dr. Phillip P. Chan M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.cytosorbents.comCytosorbents Corporation (CTSO) Latest News & Analysis
Latest News
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) CEO Dr. Phillip Chan will present at the Life Sciences Forum on June 24, 2026, with a Q&A session hosted by Zacks Analyst Thomas Kerr.
Why It Matters
CytoSorbents' upcoming presentation could influence investor sentiment by providing insights into its strategic direction and financial health, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytosorbents Corporation (CTSO) held its Q1 2026 earnings call, discussing financial performance and company updates. Detailed insights and financial figures were provided during the call.
Why It Matters
Cytosorbents' Q1 2026 earnings reveal financial health, growth prospects, and market strategies, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
2 months ago
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) reported Q1 2026 financial results and recent business highlights, focusing on blood purification for ICU and cardiac surgery.
Why It Matters
CytoSorbents' Q1 financial results and regulatory updates signal potential growth or risks, impacting stock performance and investor sentiment in the healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
2 months ago
Quick Summary
CytoSorbents Corporation (NASDAQ: CTSO) will release its Q1 2026 financial results and business updates on May 13, 2026, after market close.
Why It Matters
CytoSorbents' upcoming financial results and business updates could impact stock performance, providing insights into growth and market strategy in critical healthcare sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cytosorbents Corporation (CTSO) held its Q4 2025 earnings call, providing insights into financial performance and company updates. Further details are available in the transcript.
Why It Matters
Cytosorbents' Q4 earnings call provides insights into financial performance, growth prospects, and market strategies, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
3 months ago
Quick Summary
CytoSorbents reported 2025 revenue of $37.1M, up 4% YoY, with 71% gross margins. They secured $2.5M from an amended credit facility and are in discussions with the FDA for a new application.
Why It Matters
CytoSorbents' projected revenue growth and improved gross margins signal financial stability. Cost-cutting measures and FDA engagement could accelerate cash flow breakeven, enhancing investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CTSO Stock
What is Cytosorbents Corporation's (CTSO) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Cytosorbents Corporation (CTSO) has a median price target of $2.88. The highest price target is $5.00 and the lowest is $0.75.
Is CTSO stock a good investment in 2027?
According to current analyst ratings, CTSO has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTSO stock?
Wall Street analysts predict CTSO stock could reach $2.88 in the next 12 months. This represents a 678.3% increase from the current price of $0.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytosorbents Corporation's business model?
Cytosorbents Corporation generates revenue primarily through the sales of its flagship product, CytoSorb, a hemoadsorption cartridge that treats severe inflammatory conditions by removing harmful cytokines from the blood. The company operates in the healthcare sector, targeting intensive care units and hospital settings, and aims to enhance patient outcomes through innovative medical solutions.
What is the highest forecasted price for CTSO Cytosorbents Corporation?
The highest price target for CTSO is $5.00 from at , which represents a 1,253.5% increase from the current price of $0.37.
What is the lowest forecasted price for CTSO Cytosorbents Corporation?
The lowest price target for CTSO is $0.75 from at , which represents a 103.0% increase from the current price of $0.37.
What is the overall CTSO consensus from analysts for Cytosorbents Corporation?
The overall analyst consensus for CTSO is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.88.
How accurate are CTSO stock price projections?
Stock price projections, including those for Cytosorbents Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:22 AM UTC